Chemistry:Onfasprodil
From HandWiki
Short description: Chemical compound
![]() | |
Clinical data | |
---|---|
Other names | MIJ821 |
Drug class | NMDA receptor modulator |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H23FN2O3 |
Molar mass | 358.413 g·mol−1 |
3D model (JSmol) | |
| |
|
Onfasprodil (MIJ821) is a drug delivered via intravenous infusion that is designed as a fast-acting treatment for treatment-resistant depression. It works as a negative allosteric modulator of the NMDA receptor subunit 2B (NR2B). The drug is developed by Novartis.[1][2]
References
- ↑ Gomez-Mancilla, Baltazar; Levy, Jeffrey A.; Ganesan, Subramanian; Faller, Thomas; Issachar, Gil; Peremen, Ziv; Laufer, Offir; Shani-Hershkovich, Revital et al. (November 2023). "MIJ821 (onfasprodil) in healthy volunteers: First-in-human, randomized, placebo-controlled study (single ascending dose and repeated intravenous dose)". Clinical and Translational Science 16 (11): 2236–2252. doi:10.1111/cts.13623. PMID 37817426.
- ↑ Osaka, Hitoshi; Kanazawa, Tetsufumi (December 2023). "Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms". Psychiatry and Clinical Neurosciences Reports 2 (4). doi:10.1002/pcn5.157.
![]() | Original source: https://en.wikipedia.org/wiki/Onfasprodil.
Read more |